A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
HealthyAsthma
Interventions
DRUG

AZD5423

solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423

DRUG

AZD5423

nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423

DRUG

AZD5423

nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423

DRUG

AZD5423

nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423

Trial Locations (1)

SE1 1YR

Research Unit, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY